O

Omeros Corp
D

OMER

7.16000
USD
0.16
(2.29%)
مغلق
حجم التداول
10,985
الربح لكل سهم
-2
العائد الربحي
-
P/E
-2
حجم السوق
415,737,531
أصول ذات صلة
A
ARWR
0.380
(2.71%)
14.410 USD
F
FATE
0.09000
(7.38%)
1.31000 USD
M
MDGL
-11.63
(-3.55%)
315.49 USD
M
MRSN
-0.00300
(-0.75%)
0.39610 USD
M
MRUS
-1.140
(-2.51%)
44.210 USD
S
SRPT
0.740
(1.18%)
63.550 USD
المزيد
الأخبار المقالات

العنوان: Omeros Corp

القطاع: Healthcare
الصناعة: Biotechnology
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.